With focus on fibrosis
Poster presentation at ATS 2017 in Washington DC
19-24 May 2017
AnaMar AB develops novel, selective drugs for the treatment of a broad range of fibrotic disorders.
Read more >>
AnaMar AB is developing a portfolio of selective 5-HT2B receptor antagonists with potential use in pulmonary and dermal fibrosis.
See our pipeline >>
Targeting the extracellular matrix producing myofibroblast to treat tissue fibrosis
Learn More >>
© 2017 | AnaMar AB | Medicon Village, Scheelevägen 2 | SE-223 81 Lund, Sweden | Phone +46 46 275 62 50 |